Company Overview
Accuray Incorporated engages in the design, development, manufacture, and sale of radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. It also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, the company offers post-contract customer support, installation, training, and other professional services. It primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
Why Investors Should Care
Net profit has compounded at 23.4% per year over the last five years.
Recent Developments
- Jun 2025 Revenue of $458.50M (+2.7% YoY); net profit $-1.59M.
- Trailing 12 Months Year-on-year growth — revenue -7.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.2%, profit CAGR 23.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.17% |
| 1 Year: | -7.40% |
Compounded Profit Growth
| 5 Years: | 23.41% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -80.59% |
| 6 Months: | -70.00% |
| 3 Months: | -37.14% |
| 1 Month: | -22.35% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 23.4% over 5 years.
CONS
- Trading 85.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARAY Accuray Incorporated R2K | 0.26 | -0.68 | $30.93M | 0.00% | 5.07% | -101.06% | 2.17% | 23.41% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 90.95M | 100.33M | 99.83M | 113.79M | 95.83M | 102.32M | 103.22M | 117.42M | 89.58M | 98.83M | 99.55M | 94.98M | 85.33M | 97.46M | 102.56M | 110.94M | 107.44M | 116.28M | 96.17M | 96.49M | 114.76M | 118.06M | 103.89M | 107.24M | 101.13M | 101.55M | - | 113.24M | 127.54M | 93.94M | 102.24M | 104.84M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 81.62M | 88.56M | 67.39M | 78.17M | 79.55M |
| Gross Profit | 33.90M | 42.57M | 44.94M | 37.30M | 31.34M | 31.39M | 35.42M | 43.19M | 38.11M | 39.35M | 36.25M | 47.98M | 37.88M | 38.38M | 40.47M | 45.93M | 32.94M | 37.90M | 39.13M | 39.74M | 35.40M | 40.83M | 39.54M | 43.73M | 39.52M | 42.63M | 34.78M | 34.60M | 42.97M | 38.72M | 39.49M | 35.90M | 29.07M | 34.47M | - | 31.63M | 38.98M | 26.55M | 24.07M | 25.29M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.58M | 34.74M | 37.86M | 29.56M | 27.84M |
| Operating Income | -7.23M | -124.00K | 5.44M | - | -6.55M | -4.82M | -1.27M | - | -2.05M | -1.02M | -3.82M | - | -4.69M | -868.00K | 2.88M | - | -4.28M | 3.62M | 7.97M | - | 5.47M | 8.20M | 4.43M | - | 2.41M | 3.98M | -292.00K | -2.18M | 2.71M | 2.32M | 2.21M | -3.96M | -4.56M | -2.15M | - | 1.05M | 4.23M | -11.31M | -5.49M | -2.55M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.62M | 7.89M | -11.48M | -3.33M | -813.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.89M | 4.23M | 8.05M | 7.71M | 8.45M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -840.00K | 2.07M | -21.21M | -13.20M | -11.34M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 695.00K | 457.00K | 948.00K | 471.00K | - | 468.00K |
| Net Income | -13.03M | -6.03M | 756.00K | -7.21M | -9.93M | -9.37M | -5.03M | -5.25M | -9.38M | -4.72M | -8.85M | -946.00K | -9.21M | -4.64M | -1.18M | -1.40M | -9.36M | 10.71M | 2.62M | -152.00K | 402.00K | 4.77M | -390.00K | -11.09M | -1.03M | 179.00K | -1.05M | -5.45M | -1.87M | 599.00K | -2.97M | -9.62M | -6.34M | -3.95M | - | -1.30M | 1.12M | -21.68M | -13.77M | -11.80M |
| Diluted EPS | -0.16 | -0.08 | 0.01 | -0.09 | - | - | -0.06 | - | - | - | - | - | - | -0.05 | -0.01 | - | -0.11 | 0.12 | 0.03 | 0.00 | 0.00 | 0.05 | 0.00 | -0.12 | -0.01 | 0.00 | -0.01 | -0.06 | -0.02 | 0.01 | -0.03 | -0.10 | -0.06 | -0.04 | - | -0.01 | 0.01 | -0.18 | -0.11 | -0.09 |
| R&D Expense | 14.30M | 14.93M | 13.27M | - | 12.23M | 11.94M | 12.48M | - | 14.09M | 14.66M | 13.91M | - | 13.89M | 13.64M | 12.91M | - | 13.34M | 13.06M | 11.16M | - | 12.15M | 11.96M | 13.27M | - | 14.38M | 14.70M | 14.10M | 14.09M | 14.64M | 14.21M | 14.01M | 15.28M | 10.91M | 12.12M | 13.64M | 10.71M | - | 11.37M | 10.65M | 8.18M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 221.62M | 222.28M | 409.22M | 315.97M | 369.42M | 379.80M | 398.80M | 383.41M | 404.90M | 418.79M | 382.93M | - | 429.91M | 447.61M | 446.55M | 458.50M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 269.95M | 293.64M | 303.63M | 311.54M |
| Gross Profit | 104.02M | 107.24M | 137.27M | 97.64M | 142.80M | 145.40M | 158.71M | 141.34M | 161.69M | 162.65M | 149.72M | - | 159.96M | 153.96M | 142.92M | 146.97M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | 151.81M | 151.58M | 142.42M | 139.13M |
| Operating Income | 2.84M | -27.83M | -56.23M | -80.66M | -18.14M | -19.17M | -4.87M | -9.82M | -3.80M | 583.00K | 12.54M | - | 8.15M | 2.38M | 504.00K | 7.84M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | 11.64M | 8.37M | 5.71M | 20.24M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | 8.13M | 10.63M | 11.62M | 12.95M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | -2.00M | -6.79M | -11.82M | 1.13M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | 3.35M | 2.49M | 3.73M | 2.73M |
| Net Income | 2.84M | -26.68M | -72.04M | -103.22M | -35.45M | -40.21M | -25.50M | -29.58M | -23.90M | -16.43M | 3.83M | - | -5.35M | -9.28M | -15.54M | -1.59M |
| Diluted EPS | 0.05 | -0.44 | -1.02 | - | - | - | - | - | -0.28 | -0.19 | 0.04 | - | -0.06 | -0.10 | -0.16 | -0.02 |
| R&D Expense | 31.52M | 41.30M | 81.29M | 66.20M | 53.72M | 55.75M | 56.65M | 49.92M | 57.25M | 56.49M | 49.78M | 52.73M | 57.75M | 57.13M | 49.73M | 47.94M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 455.78M | 473.17M | 475.93M | 495.19M | 466.77M | 469.03M | 406.46M | 378.73M | 438.18M | 490.93M | - | 472.85M | 479.21M | 468.63M | 470.24M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 350.89M | 338.03M | 323.24M | 317.46M |
| Cash & Equivalents | 36.84M | 45.43M | 95.91M | 143.50M | 73.31M | 92.35M | 79.55M | 119.77M | 72.08M | 83.08M | 76.80M | 107.58M | - | 88.74M | 89.40M | 68.57M | 57.42M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | 142.25M | 145.15M | 138.32M | 141.02M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 94.44M | 74.78M | 92.00M | 83.19M |
| Total Liabilities | - | - | 215.46M | 269.30M | 369.09M | 396.64M | 390.99M | 409.37M | 359.93M | 330.10M | 388.31M | 427.29M | - | 419.66M | 425.56M | 423.54M | 389.07M |
| Current Liabilities | - | - | 203.04M | 174.17M | 155.86M | 184.57M | 169.91M | 210.21M | 284.49M | 169.43M | 192.18M | 182.27M | - | 208.86M | 198.64M | 195.27M | 192.58M |
| Long Term Debt | - | - | - | 79.47M | 198.77M | 195.61M | 199.66M | 170.51M | 51.55M | 131.08M | 159.84M | 189.31M | - | 171.91M | 171.56M | 164.40M | 123.79M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 199.49M | 205.04M | 210.75M | 176.38M |
| Total Equity | 153.90M | 170.08M | 240.33M | 203.87M | 106.83M | 98.55M | 75.78M | 59.66M | 46.53M | 48.63M | 49.87M | 63.63M | - | 53.19M | 53.66M | 45.08M | 81.17M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 93.50M | 96.53M | 100.19M | 112.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | -14.41M | 30.93M | -380.00K | 18.33M | -29.64M | -1.47M | - | -2.40M | 15.54M | -11.90M | 2.86M |
| Investing Cash Flow | - | - | - | - | - | 3.69M | 8.26M | 17.82M | 17.77M | -4.31M | -3.73M | - | -4.72M | -12.68M | -3.60M | -8.52M |
| Financing Cash Flow | - | - | - | - | - | 5.89M | -757.00K | -54.54M | -27.45M | 28.47M | 26.70M | - | -15.37M | -2.11M | -3.95M | -4.25M |
| Capital Expenditure | -5.13M | -4.02M | -10.77M | -15.13M | -11.93M | -10.45M | -8.07M | -5.03M | -6.28M | -4.31M | -3.56M | - | -4.72M | -12.68M | -3.60M | -8.52M |
| Free Cash Flow | - | - | - | - | - | -24.85M | 22.86M | -5.41M | 12.05M | -33.95M | -5.03M | - | -7.12M | 2.86M | -15.51M | -5.66M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | -22.49M | 746.00K | -19.46M | -9.91M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 0 | 14.08M | 0 | 0 | - | - |
Ratios (Annual)
Figures in %.
| Metric | Jun 2010 | Jun 2011 | Jun 2012 | Jun 2013 | Jun 2014 | Jun 2015 | Jun 2016 | Jun 2017 | Jun 2018 | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 46.9% | 48.2% | 33.5% | 30.9% | 38.7% | 38.3% | 39.8% | 36.9% | 39.9% | 38.8% | 39.1% | - | 37.2% | 34.4% | 32.0% | 32.1% |
| Operating Margin % | 1.3% | -12.5% | -13.7% | -25.5% | -4.9% | -5.0% | -1.2% | -2.6% | -0.9% | 0.1% | 3.3% | - | 1.9% | 0.5% | 0.1% | 1.7% |
| Net Margin % | 1.3% | -12.0% | -17.6% | -32.7% | -9.6% | -10.6% | -6.4% | -7.7% | -5.9% | -3.9% | 1.0% | - | -1.2% | -2.1% | -3.5% | -0.3% |
| ROE % | 1.7% | -11.1% | -35.3% | -96.6% | -36.0% | -53.1% | -42.7% | -63.6% | -49.1% | -32.9% | 6.0% | - | -10.1% | -17.3% | -34.5% | -2.0% |
| ROCE % | - | -11.0% | -18.8% | -25.2% | -5.8% | -6.5% | -1.9% | -8.1% | -1.8% | 0.2% | 4.1% | - | 3.1% | 0.8% | 0.2% | 2.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | TCW Group, Inc. | 13.00% | 15.47M | $4.11M |
| 2 | Blackrock Inc. | 7.11% | 8.46M | $2.25M |
| 3 | Neuberger Berman Group, LLC | 4.92% | 5.86M | $1.56M |
| 4 | Armistice Capital, LLC | 4.74% | 5.64M | $1.50M |
| 5 | Weber Capital Management LLC /ADV | 4.25% | 5.06M | $1.34M |
| 6 | Vanguard Capital Management LLC | 3.72% | 4.43M | $1.18M |
| 7 | Geode Capital Management, LLC | 2.00% | 2.38M | $633.07K |
| 8 | Mackenzie Financial Corporation | 1.97% | 2.35M | $623.90K |
| 9 | Renaissance Technologies, LLC | 1.93% | 2.29M | $609.17K |
| 10 | State Street Corporation | 1.70% | 2.02M | $536.49K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARAY
Accuray (ARAY) Stock Sees Fair Value Cut After Downgrades And Lower Growth Assumptions
The latest update on Accuray centers on a sharp reset in its fair value estimate, with the target reduced from US$3.88 to US$0.35. Analysts are reworking their models to reflect more cautious assumptions, and that shift is feeding directly …
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company's new Chief Commercial Officer and David Shin, the company's new Chief Legal Officer.…
Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer
Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive r…
Accuray Inc (ARAY) Runs Into Middle East Headwinds, But Shift Plan Is Working
Accuray Inc (NASDAQ:ARAY) is one of the best small cap robotics stocks to buy according to analysts. The March quarter results that Accuray Inc (NASDAQ:ARAY) reported on May 6 showed the company’s revenue decreased, and the loss widened. Th…
Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls
Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls
Accuray Slides As Insider Purchases Lose Another US$95k
The recent 17% drop in Accuray Incorporated's ( NASDAQ:ARAY ) stock could come as a blow to insiders who purchased...
ARAY — Frequently Asked Questions
What is the current share price of Accuray Incorporated (ARAY)?
As of 2026-07-14 21:23 PDT, Accuray Incorporated (ARAY) trades at $0.26 on NasdaqGS. Its 52-week range is $0.24 to $1.85.
What is the market capitalisation of ARAY?
Accuray Incorporated (ARAY) has a market capitalisation of $30.93M on NasdaqGS.
What is the P/E ratio of ARAY?
ARAY trades at a trailing price-to-earnings (P/E) ratio of -0.68. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 0.97.
What is the return on equity (ROE) of ARAY?
ARAY has a return on equity (ROE) of -101.06%. Its return on capital employed (ROCE) is 5.07%.
Is ARAY a good stock to buy?
This page provides a data-driven analysis of Accuray Incorporated (ARAY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.